“New Alzheimer’s Drug Donanemab: Amsterdam Alzheimer Center, Amsterdam UMC, and Brain Research Center Enthusiastic about Large-Scale International Research Results Showing Slowed Disease Progression in Early Stages”

2023-05-03 20:58:02

Premium

The best of De Telegraaf

Door Renate Curfs

Updated 21 min ago37 minutes ago in INTERIOR

Just under 1200 patients with early Alzheimer’s were given the new drug through an IV for 1.5 years.

Ⓒ Foto Getty Images

Amsterdam – The Amsterdam Alzheimer Center, the Amsterdam UMC and the Brain Research Center are enthusiastic about Donanemab, the new drug against Alzheimer’s. Large-scale international research shows that people who are in the early stages of the disease deteriorate less quickly with this drug. “This offers hope. This makes it conceivable that Alzheimer’s disease will one day be curable.”